Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.57 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | UBE2M | P61081 | 6/20 | 0.52 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495090 | 0.94 | MAPT (0.52) | CCR2RXFP2RXFP1UBE2MDCUN1D1 | |
| SCHEMBL5780708 | 0.90 | P2RX4 (0.46) | CCR2RXFP2RXFP1UBE2MDCUN1D1 | |
| SCHEMBL5778416 | 0.89 | TRPV1 (0.46) | CCR2RXFP2RXFP1UBE2MDCUN1D1 | |
| SCHEMBL5778367 | 0.88 | EPHX2 (0.46) | CCR2LMNAMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL5779958 | 0.87 | NPC1 (0.62) | RXFP1TP53LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5780016 | 0.85 | NPC1 (0.47) | CCR2MAPTSMN1; SMN2HTTRAB9A | |
| SCHEMBL5778493 | 0.85 | NPC1 (0.44) | CCR2UBE2MDCUN1D1ACHETP53 | |
| SCHEMBL5778441 | 0.84 | RAB9A (0.54) | LMNAMAPTSMN1; SMN2HTTRAB9A | |
| SCHEMBL5783688 | 0.84 | NPC1 (0.57) | TP53LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL5780781 | 0.84 | RAB9A (0.46) | TP53LMNAMAPTSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | claimed |
| US-6998407-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-02-14 | — | — | US | claimed |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-07-01 | — | — | US | claimed |
| EP-1383757-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-15 | — | — | US | claimed |
| WO-2002081463-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | disclosed |
| US-6677365-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; RHEUMATIC DISEASES; CARDIOVASCULAR DISORDERS | TELIK, INC. | 2004-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | CCL11, CCR1, CCR2 | CCR2 3/4885RXFP2 790/4885RXFP1 373/4885 |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | CCR2 1/4885RXFP2 541/4885RXFP1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.